Organon OGN Accrued and other current liabilities
Accrued and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept ogn:AccruedAndOtherLiabilitiesCurrent.
The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's accrued and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's accrued and other current liabilities?
- Organon (OGN) reported accrued and other current liabilities of $1.42B in Q1 2026.
- How has Organon's accrued and other current liabilities changed year-over-year?
- Organon's accrued and other current liabilities increased by 0.8% year-over-year, from $1.41B to $1.42B.
- What is the long-term trend for Organon's accrued and other current liabilities?
- Over 5 years (2020 to 2025), Organon's accrued and other current liabilities has grown at a 15.2% compound annual growth rate (CAGR), from $659M to $1.34B.
- What does accrued and other current liabilities mean?
- This metric represents the aggregate of short-term obligations that have been incurred but not yet invoiced or paid by the end of the reporting period. It typically includes items such as accrued compensation, rebates, product returns, and other operational expenses essential to the company's pharmaceutical business model. Monitoring this balance provides insight into the company's short-term liquidity requirements and the timing of its operational cash outflows.